Mayne Pharma (MAYNF) 0.6900 $MAYNF
Onychomycosis Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Sat Feb 14, 1:30AM CST
The report "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium). Onychomycosis (Tinea Unguium) is a fungal illness of the nails. It is the most common nail disease in adults. It is spread through direct contact with the yeast. Onychomycosis is caused by thickened nail, ragged nail, unsightly nail and pain in the nail. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/onychomycosi...eport.html .
ANAC: 40.76 (-0.07)
Actavis divests U.S. rights to Doryx for $50M
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:49PM CST
ACT: 285.37 (+3.71)
HedgePath Pharmaceuticals Secures Interim Financing To Commence Clinical Trials and Finalizes Key Agreement with Mayne Pharma
PR Newswire - Wed Jun 25, 8:15AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has closed a $1.5 million interim private common stock financing. The funds were secured from Hedgepath, LLC, HPPI's current majority stockholder. Under the terms of the financing, Hedgepath, LLC will purchase 20 million shares of HPPI common stock for gross proceeds of $1.5 million, which proceeds will be funded in pre-agreed to monthly tranches during the remainder of 2014.
Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zp6w5m/onychomycosis) has announced the addition of the "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects Companies Mentioned: - Actavis plc - Eisai Co., Ltd. - Nihon Nohyaku Co., Ltd. - Helix BioMedix, Inc. - Kaken Pharmaceutical Co., Ltd. - Apricus Biosciences, Inc. - NovaBay Pharmaceuticals, Inc. - Nuvo Research Inc. - Mayne Pharma Group Limited - Evolva SA - Novabiotics Ltd - Anacor Pharmaceuticals, Inc. - NB Therapeutics, Inc. - NanoBio Corporation - Moberg Pharma AB - Viamet Pharmaceuticals, Inc. - Celtic Pharmaceutical Holdings L.P. - Meiji Seika Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/zp...chomycosis
APRI: 1.84 (-0.08), ANAC: 40.76 (-0.07)
Onychomycosis Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Sat Feb 14, 1:30AM CST
The report "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium). Onychomycosis (Tinea Unguium) is a fungal illness of the nails. It is the most common nail disease in adults. It is spread through direct contact with the yeast. Onychomycosis is caused by thickened nail, ragged nail, unsightly nail and pain in the nail. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/onychomycosi...eport.html .
ANAC: 40.76 (-0.07)
Actavis divests U.S. rights to Doryx for $50M
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:49PM CST
ACT: 285.37 (+3.71)
HedgePath Pharmaceuticals Secures Interim Financing To Commence Clinical Trials and Finalizes Key Agreement with Mayne Pharma
PR Newswire - Wed Jun 25, 8:15AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has closed a $1.5 million interim private common stock financing. The funds were secured from Hedgepath, LLC, HPPI's current majority stockholder. Under the terms of the financing, Hedgepath, LLC will purchase 20 million shares of HPPI common stock for gross proceeds of $1.5 million, which proceeds will be funded in pre-agreed to monthly tranches during the remainder of 2014.
Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zp6w5m/onychomycosis) has announced the addition of the "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects Companies Mentioned: - Actavis plc - Eisai Co., Ltd. - Nihon Nohyaku Co., Ltd. - Helix BioMedix, Inc. - Kaken Pharmaceutical Co., Ltd. - Apricus Biosciences, Inc. - NovaBay Pharmaceuticals, Inc. - Nuvo Research Inc. - Mayne Pharma Group Limited - Evolva SA - Novabiotics Ltd - Anacor Pharmaceuticals, Inc. - NB Therapeutics, Inc. - NanoBio Corporation - Moberg Pharma AB - Viamet Pharmaceuticals, Inc. - Celtic Pharmaceutical Holdings L.P. - Meiji Seika Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/zp...chomycosis
APRI: 1.84 (-0.08), ANAC: 40.76 (-0.07)
